On September 25, 2024, Gregory Weinhoff, Chief Business Officer of Centessa Pharmaceuticals PLC (CNTA, Financial), executed a sale of 16,619 shares of the company. Following this transaction, the insider now directly owns 206,750 shares in the company. The shares were sold at a price of $15.69, as detailed in the SEC Filing.
Centessa Pharmaceuticals PLC (CNTA, Financial) is a biopharmaceutical company focused on discovering, developing, and delivering meaningful therapies for patients. The company aims to bring innovative treatments across various disease areas through its unique research and development model.
Over the past year, Gregory Weinhoff has sold a total of 101,619 shares and has not made any purchases of the company's stock. This recent transaction is part of a broader trend observed within the company, where there have been 10 insider sells and no insider buys over the past year.
The stock of Centessa Pharmaceuticals PLC (CNTA, Financial) was trading at $15.69 on the day of the sale, giving the company a market cap of approximately $2.03 billion. This valuation reflects the company's current price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow.
The insider transaction trends for Centessa Pharmaceuticals PLC (CNTA, Financial) can be visualized in the following chart:
This insider activity may be of interest to investors tracking ownership changes and seeking insights based on insider behaviors. For more detailed valuation metrics such as the GF Value, investors are encouraged to review additional financial data and stock performance metrics.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
